TROVAGENE INC | 5,272 Euro | +0,408 +8,39 % | |
| WKN: A1JY4B ISIN: US8972383090 Ticker-Symbol: XE7A | Frankfurt | 24.05.13 | 08:01 Uhr |
Branche BiotechnologieAktienmarkt Sonstige |
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 15.05. | Trovagene, Inc. - 8-K, Current Report | - | SEC Filings | |
| 14.05. | Trovagene, Inc. Announces First Quarter 2013 Earnings | 46 | PR Newswire | |
| SAN DIEGO, May 14, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:TROV), a developer of transrenal molecular diagnostics, today reported its financial results for the three months ended March 31, 2013.... Mehr lesen zu: Trovagene, Inc. Announces First Quarter 2013 Earnings | ||||
| 06.05. | Highline Research Advisors initiates coverage on Trovagene (NASDAQ:TROV) with a buy rating. | 30 | PR Newswire | |
| NEW YORK, May 6, 2013 /PRNewswire/ --Today Highline Research Advisors initiated coverage through Empire Asset Management Company, a FINRA member (143007) of Trovagene (NASDAQ:TROV) with a BUY rating... Mehr lesen zu: Highline Research Advisors initiates coverage on Trovagene (NASDAQ:TROV) with a buy rating. | ||||
| 30.04. | Will The Latest PerkinElmer Agreement Help TrovaGene Tap Into A $22 Billion Market? | - | Seeking Alpha | |
| 30.04. | Trovagene 'Ups The Ante' With PerkinElmer Collaboration | 1 | Seeking Alpha | |
| 26.04. | PerkinElmers' Collaboration: Testimony To The Strength Of Trovagene's Novel Technology Platform | - | Seeking Alpha | |
| 02.04. | Trovagene Advances Next-Gen Version Of Qiagen's HPV Test | 82 | Seeking Alpha | |
| 01.04. | Trovagene, Inc., Announces Fourth Quarter and Year End 2012 Earnings | 52 | PR Newswire | |
| SAN DIEGO, April 1, 2013 /PRNewswire/ --Trovagene, Inc. (NASDAQ:TROV), a developer of transrenal molecular diagnostics, today reported its financial results for the three months and the year ended... Mehr lesen zu: Trovagene, Inc., Announces Fourth Quarter and Year End 2012 Earnings | ||||
| 01.04. | Trovagene launches HPV assay | - | Pharma Bus Review | |
| 28.03. | Trovagene's Novel Diagnostics Platform To Garner Attention In 2013 | - | Seeking Alpha | |
| 27.03. | Trovagene (TROV) Announces non-Invasive HPV-HR Test Now Commerically Available | - | StreetInsider.com | |
| 27.03. | Trovagene Launches Urine-Based HPV Test | 42 | PR Newswire | |
| SAN DIEGO, March 27, 2013 /PRNewswire/ --Trovagene, Inc. (NASDAQ:TROV), today announced the commercial availability of its urine-based HPV-HR (high-risk) assay, a molecular human papillomavirus (HPV)... Mehr lesen zu: Trovagene Launches Urine-Based HPV Test | ||||
| 12.03. | Trovagene to Present at 25th Annual Roth Conference | 35 | PR Newswire | |
| SAN DIEGO, March 12, 2013 /PRNewswire/ --Trovagene, Inc. (NASDAQ:TROV), a developer of transrenal molecular diagnostics, today announced that Chief Financial Officer Stephen Zaniboni is scheduled... Mehr lesen zu: Trovagene to Present at 25th Annual Roth Conference | ||||
| 04.03. | Trovagene Appoints Mark Erlander, Ph.D. as Chief Scientific Officer | 34 | PR Newswire | |
| SAN DIEGO, March 4, 2013 /PRNewswire/ --Trovagene, Inc. (NASDAQ:TROV), a developer of transrenal molecular diagnostics, today announced that Mark Erlander, Ph.D., has joined the company as chief scientific... Mehr lesen zu: Trovagene Appoints Mark Erlander, Ph.D. as Chief Scientific Officer | ||||
| 01.03. | Rate Of HPV-Related Oral Cancers Highlights Need For Early Detection; Trovagene Poised To Fulfill Needs | - | Seeking Alpha | |
| 12.02. | Trovagene Announces Commercial Launch Timelines for HPV Carrier and Oncogene Mutation Tests | 53 | PR Newswire | |
| SAN DIEGO, Feb. 12, 2013 /PRNewswire/ --Trovagene, Inc. (NASDAQ:TROV) today announced that the development of its proprietary, urine-based HPV carrier screening test is progressing well... Mehr lesen zu: Trovagene Announces Commercial Launch Timelines for HPV Carrier and Oncogene Mutation Tests | ||||
| 06.02. | Trovagene to Present at Leerink Swan Global Healthcare Conference | 30 | PR Newswire | |
| SAN DIEGO, Feb. 6, 2013 /PRNewswire/ --Trovagene, Inc. (NASDAQ:TROV), a developer of transrenal molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled... Mehr lesen zu: Trovagene to Present at Leerink Swan Global Healthcare Conference | ||||
| 18.01. | Trovagene Keeps The Pace In 2013 | 1 | Seeking Alpha | |
| 03.01. | Trovagene to Study Transrenal BRAF Mutations in Primary and Metastatic Cancers | 65 | PR Newswire | |
| SAN DIEGO, Jan. 3, 2013 /PRNewswire/ --Trovagene, Inc. (Nasdaq:TROV), a developerof transrenal molecular diagnostics, announced that it has entered into a clinical collaboration with... Mehr lesen zu: Trovagene to Study Transrenal BRAF Mutations in Primary and Metastatic Cancers | ||||
| 27.12. | Trovagene, Inc., Grants License for NPM1 Marker for Acute Myelogenous Leukemia to Leading Academic Medical Center | 75 | PR Newswire | |
| SAN DIEGO, Dec. 27, 2012 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:TROV), a developer of transrenal molecular diagnostics, announced it has granted Duke University and Duke University Health... Mehr lesen zu: Trovagene, Inc., Grants License for NPM1 Marker for Acute Myelogenous Leukemia to Leading Academic Medical Center | ||||
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| AFFYMETRIX | 2,80 | -1,13 % | Affymetrix Names Gavin Wood EVP & CFO |
| NEUROCRINE BIOSCIENCES | 9,749 | +5,98 % | Neurocrine Biosciences to Present At The Deutsche Bank 38th Annual dbAccess Health Care Conference |
| ONYX PHARMACEUTICALS | 74,41 | +0,61 % | Onyx Pharmaceuticals Announces Data Presentations at the 18th Congress of the European Hematology Association |
| MYRIAD GENETICS | 24,814 | +0,46 % | Myriad Genetics: Höhenflug dank Jolie |
| AMPLIPHI BIOSCIENCES | 0,109 | -2,68 % | AmpliPhi Receives Notice of Allowance on Key Patent for its Bacteriophage Therapy to Treat Drug-resistant Biofilm-based Infections |
